- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Challenges With Personalized Medicine
Personalized medicine and diagnostic testing are yet to witness widespread adoption. While there are several reasons for this, David C. Collymore, MD, MBA, would like to sum these challenges into 2 specific buckets. The primary challenge, he believes, are cost and reimbursement. “If insurance companies are not covering the cost of the test, [the test] will be less accessible to the general population. Those that can afford the cost of the testing will go ahead and get it, but the overall population may not have access to it if that’s the case. Reimbursement by managed care is a hurdle for any advancement in healthcare,” Collymore said.
The other challenge is building additional evidence and the need to conduct more studies in a larger patient population. Collymore believes time can help surmount this hurdle. “We need time, we need the tests to be reimbursed, and we need the studies to display evidence of the care. These I think are the 2 main challenges.”
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
